MedTrace Logo

PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

NCT05122260 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-04-29

No results posted yet for this study

Summary

This is the first-in-human clinical study to see if a single dose of an investigational nasal spray made from a modified plant protein called Q-Griffithsin is safe, tolerated and acceptable for use by healthy adults 18 to 60 years of age.

Conditions

  • COVID-19 Prevention

Interventions

DRUG

Q-Griffithsin

intranasal spray administered as a single dose

OTHER

Placebo

intranasal spray administered as a single dose

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Kenneth Palmer

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2022-01-27
Completion
2022-02-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05122260 on ClinicalTrials.gov